Market

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Read More

Related Posts

Oil heads for first monthly drop since November as economic uncertainty weighs

Oil heads for first monthly drop since November as econ...

Dell sees its backlog swell as big AI deals come through

Dell sees its backlog swell as big AI deals come through

Japan factory output contracts as expected in Jan, retail sales jump

Japan factory output contracts as expected in Jan, reta...

Alliance Entertainment CEO Jeffrey Walker buys $2.69 billion in stock

Alliance Entertainment CEO Jeffrey Walker buys $2.69 bi...

SS&C Technologies director Michael Zamkow sells $2.03 million in stock

SS&C Technologies director Michael Zamkow sells $2.03 m...

Csg Systems director Ronald Cooper sells $599,580 in stock

Csg Systems director Ronald Cooper sells $599,580 in stock